Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels

• Background: There have been concerns about the cardiovascular safety of omalizumab. less thanbrgreater than less thanbrgreater thanObjectives: In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated. less thanbrgreater than less thanbrgreater thanMaterials and methods: In a pilot study described below we examined the levels of serum eosinophil cationic peptid (ECP), CD200, d-dimer, 25-hydroxyvitamin D (25(OH) D), CXCL8 and IL-1 beta in asthma patients treated with anti-IgE therapy, to explore their relationship with disease activity, and the impact of anti-IgE therapy impact on those levels. Exercise stress testing and blood samples were taken at all follow up visits from the time of first diagnosis and after 20 months of treatment during the disease remission. less thanbrgreater than less thanbrgreater thanResults: Fractional exhaled nitric oxide concentrations and serum levels of sTRAIL, sCD200, D-dimer, ECP, total IgE, IL-1 beta and Hs-CRP were decreased while CXCL8, 25(OH) D were increased after starting the treatment of anti-IgE. Our first case of a patient, who had both protein C and S deficiency and hence a high risk for thromboembolism, documents for the first time the safety of omalizumab for asthmatic patients with concurrent risk factors contributing to arteriothrombotic events. less thanbrgreater than less thanbrgreater thanConclusion: Omalizumab might be used carefully in patients with cardiovascular diseases.

Nyckelord

25-hydroxyvitamin D

asthma

cardiovascular risk

CXCL8

IL-1 beta

omalizumab

protein C and S deficiency

sCD200

MEDICINE

MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)